CompletedPhase 2NCT00088218

Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

Studying C syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Stefan Faderl, MD
M.D. Anderson Cancer Center
Intervention
Clofarabine(drug)
Enrollment
95 enrolled
Eligibility
60 years · All sexes
Timeline
20042008

Study locations (1)

Collaborators

Genzyme, a Sanofi Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00088218 on ClinicalTrials.gov

Other trials for C syndrome

Additional recruiting or active studies for the same condition.

See all trials for C syndrome

← Back to all trials